{"nctId":"NCT03280615","briefTitle":"Omega 3 Fatty Acids in Patients With Chronic Renal Disease","startDateStruct":{"date":"2017-09-20","type":"ACTUAL"},"conditions":["Renal Insufficiency, Chronic"],"count":100,"armGroups":[{"label":"Omega 3 fatty acids","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Omega 3 fatty acids"]},{"label":"Corn oil","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Corn oil"]}],"interventions":[{"name":"Omega 3 fatty acids","otherNames":[]},{"name":"Corn oil","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Urinary albumin excretion over 30 mg/g creatinin\n* Chronic renal failure stage 2 to 4\n* Absence of serious conditions such as c√°ncer, decompensated heart failure, chronic infections and severe arterial lesions\n\nExclusion Criteria:\n\n* Blood glucose levels over 180 mg/dl or glycosilated hemoglobin over 8%\n* Presence of cognitive impairment that does not allow to sigin a written informed consent\n* Alcohol or illicit drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a Urine Albumin Excretion Decrease of 20% or More","description":"Number of participants in whom urine albumin excretion in a spot urine sample at the end of follow up, expressed as mg/g creatinine, decreased by 20% or more","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in C Reactive Protein Levels at 12 Weeks of Intervention","description":"Blood C reactive protein measured at baseline and the end of the intervention.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Wave Velocity at 12 Weeks of Intervention","description":"Measurement of pulse wave velocity using a oscillometric device measured at baseline and end of follow up and expressed ad m/s","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["Minor complaints","Nausea, vomiting or diarrhea"]}}}